PR Newswire - Ligufalimab (CD47)-Based Combination Achieves Deep...
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (...
Read More

ภาษาไทย
English